Ablynx Competitors and Similar CompaniesClear all
Ablynx's competitors and similar companies include ImmunoGen, CytomX Therapeutics and Genfit.
 Ablynx Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. |  Genfit GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs. | |
Founding Date | Founding Date 2001 | Founding Date 1981 | Founding Date 2008 | Founding Date 1999 |
Type | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Gent, BE HQ | Locations Waltham, US HQ | Locations South San Francisco, US HQ | Locations Loos, FR HQ Cambridge, US |
Employees | Employees 1401% decrease | Employees 277161% increase | Employees 15815% increase | Employees 1696% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 8.7 b | Valuation ($) 78 m | Valuation ($) 280.8 m |
Financial | ||||
Revenue (est.) | Revenue (est.) €85.2m (FY, 2016) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) $101.2m (FY, 2023) | Revenue (est.) €28.6m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $176k (FY, 2022) | Cost of goods N/A | Cost of goods €547k (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit $108.6m (FY, 2022) | Gross profit N/A | Gross profit €38.1m (FY, 2023) |
Net income | Net income (€1.1m) (FY, 2016) | Net income ($222.9m) (FY, 2022) | Net income ($569k) (FY, 2023) | Net income (€28.9m) (FY, 2023) |
Operating ⚠ | ||||
Patents (Foreign) | Patents (Foreign) 180 (Q2, 2017) | Patents (Foreign) N/A | Patents (Foreign) 4 (FY, 2016) | Patents (Foreign) 450 (FY, 2019) |
Patents (US) | Patents (US) 50 (Q2, 2017) | Patents (US) N/A | Patents (US) 13 (FY, 2016) | Patents (US) 28 (FY, 2019) |
Funding | ||||
Total funding raised | Total funding raised $ 498.8m | Total funding raised $ 56m | Total funding raised $ 132.4m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
ImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View companyCytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View companyGenfit
HQ
Loos, FR
Employees
169↑ 6% increase
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs.
View company